Technical Analysis for CTIC - Cell Therapeutics, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Down |
Historical CTIC trend table... |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Wide Bands | Range Expansion | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
Hammer Candlestick | Bullish | 4.98% | |
Lizard Bullish | Bullish Day Trade Setup | 4.98% | |
Doji - Bullish? | Reversal | 4.98% | |
Wide Bands | Range Expansion | 4.98% | |
Oversold Stochastic | Weakness | 4.98% | |
Fell Below 200 DMA | Bearish | 4.12% | |
180 Bearish Setup | Bearish Swing Setup | 4.12% | |
Inside Day | Range Contraction | 4.12% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
Alert | Time |
---|---|
60 Minute Opening Range Breakout | about 14 hours ago |
Up 5% | about 14 hours ago |
2x Volume Pace | about 14 hours ago |
Lizard Bullish Entry | about 15 hours ago |
Hammer Candlestick Entry | about 15 hours ago |
Get a Trading Assistant
- Earnings date: 03/17/2021
Cell Therapeutics, Inc. Description
Cell Therapeutics, Inc. engages in the acquisition, development, and commercialization of treatments for cancer. The company primary focuses on the commercialization of PIXUVRI, an aza-anthracenedione derivative, which is in Phase III clinical trials for the treatment of multiply relapsed or refractory aggressive non-Hodgkin lymphoma. It is also developing Opaxio, a chemotherapeutic agent that is in Phase III clinical trials for the treatment of ovarian cancer; in Phase II clinical trials for the treatment of malignant brain cancer; and in Phase I-II clinical trials for the treatment of head and neck cancer. In addition, the company is developing Pacritinib, a Janus kinase 2 inhibitor that is in Phase III clinical trials for the treatment of myelofibrosis; Tosedostat, an aminopeptidase inhibitor that is in Phase I-II clinical trials for the treatment of acute myeloid leukemia; and Brostallicin, which is in Phase II clinical trials for the treatment of triple-negative breast cancer. It has a license and co-development agreement with Chroma Therapeutics, Ltd. to develop and commercialize Tosedostat. Cell Therapeutics, Inc. was founded in 1991 and is headquartered in Seattle, Washington.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Chemical Compounds Organic Compounds Lymphoma Cancer Treatments Breast Cancer Treatment Of Breast Cancer Ovarian Cancer Acute Myeloid Leukemia Ethers Antibody Drug Conjugates Head And Neck Cancer Janus Brain Cancer Treatment Of Acute Myeloid Leukemia Treatment Of Ovarian Cancer Hodgkin Lymphoma Pyrrolidines Triple Negative Breast Cancer Camidanlumab Tesirine Janus Kinase Myelofibrosis Pacritinib Pixantrone Treatment Of Head And Neck Cancer
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 4.13 |
52 Week Low | 0.86 |
Average Volume | 1,102,015 |
200-Day Moving Average | 2.59 |
50-Day Moving Average | 3.10 |
20-Day Moving Average | 2.78 |
10-Day Moving Average | 2.56 |
Average True Range | 0.22 |
ADX | 10.33 |
+DI | 25.66 |
-DI | 24.23 |
Chandelier Exit (Long, 3 ATRs ) | 3.48 |
Chandelier Exit (Short, 3 ATRs ) | 2.95 |
Upper Bollinger Band | 3.36 |
Lower Bollinger Band | 2.19 |
Percent B (%b) | 0.29 |
BandWidth | 41.88 |
MACD Line | -0.19 |
MACD Signal Line | -0.17 |
MACD Histogram | -0.0163 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 2.76 | ||||
Resistance 3 (R3) | 2.74 | 2.65 | 2.72 | ||
Resistance 2 (R2) | 2.65 | 2.59 | 2.66 | 2.70 | |
Resistance 1 (R1) | 2.59 | 2.56 | 2.62 | 2.61 | 2.69 |
Pivot Point | 2.50 | 2.50 | 2.52 | 2.51 | 2.50 |
Support 1 (S1) | 2.44 | 2.44 | 2.47 | 2.46 | 2.37 |
Support 2 (S2) | 2.35 | 2.41 | 2.36 | 2.36 | |
Support 3 (S3) | 2.29 | 2.35 | 2.34 | ||
Support 4 (S4) | 2.31 |